Improving Outcomes in Metastatic HER2+ Breast Cancer: Translating Evidence to Clinical Practice : Episode 3

HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond

May 22, 2023

Kevin Kalinsky, MD, MS

A key opinion leader in HER2+ metastatic breast cancer shares his perspective on key factors in selecting second or later-line therapy.

EP: 1.Landscape of HER2+ Metastatic Breast Cancer: Patient Overview

EP: 2.HER2+ Metastatic Breast Cancer: An Evolving Treatment Armamentarium

EP: 3.HER2+ Metastatic Breast Cancer: Factors in Selecting 2L Therapy and Beyond

EP: 4.Role of T-DXd in Patients With HER2+ Metastatic Breast Cancer and CNS Metastasis

EP: 5.HER2+ Breast Cancer With CNS or Leptomeningeal Metastases: Future Directions in Care

EP: 6.Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

EP: 7.Overview of the HER2+ Metastatic Breast Cancer Treatment Armamentarium

Related Videos

Ann H. Partridge, MD, MPH

Adrienne G. Waks, MD,

Erika P. Hamilton, MD

Aditya Bardia, MD, MPH

Sara M. Tolaney, MD, MPH

Expert on breast cancer

Expert on RCC

Experts on RCC

Expert on breast cancer

Related Content

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Related Content

Sara M. Tolaney, MD, MPH

Sacituzumab Govitecan Displays OS Benefit in Pretreated HR+/HER2– Breast Cancer

Francois-Clement Bidard, MD, PhD

FDA Approval Insights: Elacestrant in ER+/HER2– ESR1-mutated Advanced or Metastatic Breast Cancer

March 30th 2023

Ezra Rosen, MD, PhD

Zotatifin Triplet Shows Promising Activity, Low Toxicity in Heavily Pretreated ER+ Breast Cancer

Patrick I. Borgen, MD; Laura J. Esserman, MD, MBA; Kelly K. Hunt, MD, FACS, FSSO; Kevin Kalinsky, MD, MS; Lisa A. Carey MD, ScM, FASCO, Steven J. Chmura, MD, PhD

Breast Cancer Experts Review 2023 MBCC Research Updates and the Importance of Multidisciplinary Collaboration

March 27th 2023

$Treatment with elranatamab monotherapy produced early, deep, and durable responses in patients with relapsed/refractory multiple myeloma who received a prior BCMA-directed therapy, according to a pooled analysis of the MagnetisMM-1, MagnetisMM-2, MagnetisMM-3, and MagnetisMM-9 trials.$

Elranatamab Elicits Responses in Relapsed/Refractory Myeloma After Prior BCMA-directed Therapy

A clinically meaningful absolute risk reduction in invasive disease-free survival and distant relapse-free survival with abemaciclib plus endocrine therapy was maintained in patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer regardless of age.

Efficacy and Safety of Abemaciclib Plus ET Is Maintained Older Patients with HR+, HER2–, Early Breast Cancer

Latest Conference Coverage

Ruxolitinib Improves Spleen Volume, TSS in Myelofibrosis Irrespective of Anemia, Transfusion Status

Radiotherapy Can Be Safely Omitted in PMBCL With CMR After Chemoimmunotherapy

Dr Mohty on Extended Follow-up Data from MagnetisMM-3 With Elranatamab in R/R Myeloma

Jaktinib Displays Significant Benefit Vs Hydroxyurea in Intermediate-2/High-Risk Myelofibrosis

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.